West Syndrome (Infantile Spasms): First-Line Treatment
For West syndrome (infantile spasms), hormonal therapy with either ACTH or high-dose oral corticosteroids should be the first-line treatment, with ACTH preferred over vigabatrin for most infants to optimize both seizure control and long-term neurodevelopmental outcomes.
Treatment Algorithm
First-Line Therapy Selection
Hormonal therapy is the standard of care for most infants with West syndrome, with two primary options 1:
- ACTH (adrenocorticotropic hormone): Low-dose ACTH is probably as effective as high-dose ACTH and should be considered for treatment 1
- High-dose oral prednisolone (40-60 mg/day): Demonstrates 64% electroclinical response within two weeks, with 62% remaining spasm-free at three months 2
Vigabatrin as first-line is reserved for specific etiologies 1:
- Tuberous sclerosis complex (TSC) - where vigabatrin is the preferred agent
- When hormonal therapy is contraindicated or unavailable
Evidence Supporting Hormonal Therapy Priority
ACTH demonstrates superior efficacy compared to vigabatrin for short-term treatment in non-TSC cases 1. More importantly, hormonal therapy (ACTH or prednisolone) leads to better long-term developmental outcomes compared to vigabatrin in cryptogenic infantile spasms 1.
The choice between ACTH and oral corticosteroids involves practical considerations 2, 3:
- ACTH: Historically first-line but involves intramuscular injections with significant logistical and financial barriers 2
- High-dose prednisolone: Represents a less expensive, readily available alternative with comparable efficacy (64% response rate) and manageable side effects 2
Dosing Protocols
For ACTH 1:
- Low-dose regimens are as effective as high-dose for short-term treatment
- Typical duration: 2 weeks followed by dose tapering 3
For oral prednisolone 2:
- Dose: 40-60 mg/day
- Duration: 14 days of treatment has been considered effective and well tolerated 3
- Taper schedule after initial treatment period
For vigabatrin (when used) 3:
- Dose: 50-150 mg/kg/day
- Critical caveat: Retinal toxicity occurs in 21-34% of infants, most frequently when treatment exceeds 6 months 3
Timing Considerations
Shorter lag time to treatment is critical 1:
- Early treatment leads to better long-term developmental outcomes
- Prompt initiation of therapy after diagnosis is essential for optimal outcomes 3
Side Effect Management
Common adverse effects with hormonal therapy include 2:
- Irritability, weight gain, and gastroesophageal reflux (52% experience side effects)
- Major adverse events are uncommon (5%) but include gastrointestinal bleeding, infection reactivation, and necrotizing enterocolitis 2
Monitoring strategies vary across centers but commonly include 4:
- Gastrointestinal prophylaxis (79% of treatment protocols)
- Blood pressure monitoring (79% of treatment protocols)
Second-Line and Combination Approaches
If first-line therapy fails 4:
- 63% of major epilepsy centers endorse sequential approach (trying hormonal therapy, then vigabatrin, or vice versa)
- 17% recommend combination therapy with both hormonal treatment and vigabatrin for all children
- Other options include ketogenic diet (mentioned in 58% of protocols) or epilepsy surgery evaluation (46% of protocols) 4
Common Pitfalls to Avoid
Do not withhold standard therapy based on absence of classic hypsarrhythmia, as many children with infantile spasms will not demonstrate this classic EEG pattern 5.
Do not delay treatment while pursuing extensive etiologic workup - the lag time to treatment directly impacts developmental outcomes 1.
Do not use vigabatrin as first-line in non-TSC cases when hormonal therapy is available, as this may compromise long-term developmental outcomes 1.